Shares of MicroVision surged +10.4% to $1.44 on October 29, bucking a down market, after the lidar sensor maker posted Q3 results that showed real commercial traction for the first time — and promised even faster growth ahead. The question for investors: does accelerating revenue matter if the company is still burning cash far faster than it earns it?
Revenue Jumped Tenfold, but Still Missed the Street's Forecast. Q3 revenue came in at $2.4 million, up from just $0.2 million a year ago — a dramatic leap that matched the entire first half of 2026 in a single quarter . Yet sales came in slightly below the $2.5 million analysts expected, even as the per-share loss of $0.45 beat estimates of a $0.75 loss . The gap between revenue growth and profitability underscores the core tension: MicroVision is selling more product, but it's still nowhere near breakeven.
The Guidance Math Demands a Massive Q4. Management reaffirmed full-year 2026 revenue guidance of $10 million–$15 million and said 2027 revenue is expected to double . With only $4.8 million booked through September , hitting even the low end requires $5.2 million in Q4 — more than double Q3. Management says $10 million in existing purchase orders awaiting shipment supports that target, but converting backlog into recognized revenue in one quarter is execution-heavy.
Cash Is the Real Clock. MicroVision ended Q3 with $28.9 million in cash . Operating cash burn hit $49.2 million through nine months, with the company on track for roughly $60 million for full-year 2026 and targeting ~$40 million in 2027 . A 28% workforce reduction supports the lower 2027 target . Still, management acknowledged it may need additional financing and is evaluating dilutive options including a $40 million at-the-market stock-sale facility — meaning existing shareholders could see their stakes shrink.
A Micro Market Cap Leaves Little Room for Error. At $1.44 per share and roughly 22.3 million shares outstanding, the market cap sits near $32 million . Even if MicroVision hits $15 million in 2026 sales, the stock trades at barely 2× revenue — cheap if growth continues, but justified if dilution and cash drain persist. Gross margin flipping to 50% from deeply negative a year ago is encouraging, yet the company must prove it can scale without consuming itself financially. The next two quarters will decide whether this is a turnaround — or a countdown.